This federal Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) provides $1,219,222.00 to support the continued development and commercialization of Nirrin Technologies' proprietary tunable laser spectrometry system, the NXT platform. The NXT system is designed to enable rapid, real-time analysis of biopharmaceutical active pharmaceutical ingredients (APIs) and excipients, helping manufacturers ensure product integrity and compliance with FDA requirements. Under this Phase II SBIR effort, Nirrin Technologies will optimize the NXT system design, fabricate 6 beta units, and conduct internal and external validation testing with major biopharmaceutical companies. This work is expected to accelerate the commercialization of Nirrin's tunable laser spectroscopy products and reduce manufacturing errors during biopharmaceutical production. The award period runs from September 3, 2024 through July 31, 2026.
Generated 3/18/25, 3:37 AM